Rajkot-based Anlon Healthcare Limited has announced its initial public offering (IPO) with a price band of ₹86–91 per share, opening on August 26, 2025. The issue, sized at nearly ₹121 crore, will fund manufacturing expansion, working capital, and debt repayment.
Anlon Healthcare Limited, a pharmaceutical company headquartered in Rajkot, Gujarat, has fixed the price band of its initial public offering (IPO) at ₹86–91 per share. The issue will open for subscription on August 26, 2025, and close on August 29, 2025. The anchor book opens a day earlier, on August 25.
The IPO comprises a fresh issue of 1.33 crore equity shares, aggregating to ₹121 crore at the upper band. The basis of allotment will be finalised on September 1, while refunds and credit of shares to investors’ demat accounts are scheduled for September 2. The company’s shares are expected to debut on the stock exchanges on September 3, 2025.
The proceeds from the public issue will be allocated across multiple strategic requirements:
- ₹30.7 crore for expanding its manufacturing facility
- ₹43.15 crore for funding working capital
- A portion for debt repayment
- Balance towards general corporate purposes
Interactive Financial Services is acting as the sole book running lead manager for the IPO.
Anlon Healthcare operates in the pharmaceutical manufacturing sector, producing active pharmaceutical ingredients (APIs), intermediates, and finished formulations. Its products cater to advanced pharma needs, supplying both domestic and international markets.
Financially, the company has shown improving profitability. For the fiscal year ending March 2024, it posted a net profit of ₹9.65 crore, compared with ₹5.82 crore in the previous year, despite a decline in revenue from ₹112.9 crore to ₹66.6 crore. For the ten months ended January 2025, profit stood at ₹12 crore on revenue of ₹77.2 crore, indicating resilience in operations and cost efficiency.
With peers such as Kronox Lab Sciences, AMI Organics, and Supriya Lifescience already established in the market, Anlon Healthcare aims to strengthen its position through capacity expansion and capital infusion from the IPO.
READ MORE ON